DH vs. CERT, EVCM, MTTR, KARO, QUBT, LSPD, VNET, FORTY, OPRA, and SEMR
Should you be buying Definitive Healthcare stock or one of its competitors? The main competitors of Definitive Healthcare include Certara (CERT), EverCommerce (EVCM), Matterport (MTTR), Karooooo (KARO), Quantum Computing (QUBT), Lightspeed Commerce (LSPD), VNET Group (VNET), Formula Systems (1985) (FORTY), Opera (OPRA), and Semrush (SEMR). These companies are all part of the "computer software" industry.
Definitive Healthcare vs.
Certara (NASDAQ:CERT) and Definitive Healthcare (NASDAQ:DH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
74.0% of Certara shares are held by institutional investors. Comparatively, 98.7% of Definitive Healthcare shares are held by institutional investors. 2.3% of Certara shares are held by company insiders. Comparatively, 16.3% of Definitive Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Certara has a net margin of -8.34% compared to Definitive Healthcare's net margin of -142.38%. Certara's return on equity of 3.43% beat Definitive Healthcare's return on equity.
Certara received 4 more outperform votes than Definitive Healthcare when rated by MarketBeat users. Likewise, 34.57% of users gave Certara an outperform vote while only 26.67% of users gave Definitive Healthcare an outperform vote.
In the previous week, Certara had 7 more articles in the media than Definitive Healthcare. MarketBeat recorded 8 mentions for Certara and 1 mentions for Definitive Healthcare. Certara's average media sentiment score of 1.31 beat Definitive Healthcare's score of 0.98 indicating that Certara is being referred to more favorably in the media.
Certara has higher revenue and earnings than Definitive Healthcare. Certara is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.
Certara presently has a consensus target price of $15.67, indicating a potential upside of 34.02%. Definitive Healthcare has a consensus target price of $5.10, indicating a potential upside of 54.55%. Given Definitive Healthcare's higher possible upside, analysts plainly believe Definitive Healthcare is more favorable than Certara.
Certara has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, Definitive Healthcare has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
Summary
Certara beats Definitive Healthcare on 14 of the 18 factors compared between the two stocks.
Get Definitive Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for DH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Definitive Healthcare Competitors List
Related Companies and Tools
This page (NASDAQ:DH) was last updated on 5/21/2025 by MarketBeat.com Staff
